Premium
Change of Causative Organisms under Antifungal Treatment in Immunosuppressed Patients with HIV‐Infections
Author(s) -
Just G.,
Steinheimer D.,
Schnellbach M.,
Böttinger C.,
Helm E.B.,
Stille W.
Publication year - 1989
Publication title -
mycoses
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.13
H-Index - 69
eISSN - 1439-0507
pISSN - 0933-7407
DOI - 10.1111/j.1439-0507.1989.tb02310.x
Subject(s) - ketoconazole , fluconazole , candida albicans , azole , candida glabrata , microbiology and biotechnology , esophageal candidiasis , antifungal , human immunodeficiency virus (hiv) , corpus albicans , itraconazole , medicine , mycosis , antifungal drugs , biology , dermatology , immunology , viral disease
Summary: Oral and esophageal candidosis are very common in HIV‐infected patients. Due to the lack of efficacy of topical antimy‐cotics in advanced stages of HIV‐infection oral azoles are mainly used for treatment. holes most often used are ketoconazole and fluconazole. While Candida albicans clearly is the most frequently encountered yeast before and after treatment other species can be found somewhat less frequently after treatment. This especially applies to Candida glabrata. Candida spp. other than C. albicans obviously may cause manifest oral candidosis. This shift of microbes deserves the more interest as they are less susceptible to azole drugs.